Genedata Announces New Solution for CRISPR Data Management and Analysis
BASEL, Switzerland (PRWEB) January 11, 2018 -- Genedata, a leading provider of advanced software solutions for R&D, today announced the release of Genedata Selector for Precise Genome Editing, an innovative solution for data management and analysis of CRISPR related genomic data. Genedata Selector for Precise Genome Editing targets research organizations that require an infrastructure solution that tracks experimental data throughout the genome editing process as well as streamlines and automates the data flows from target gene specification to guideRNA selection to genotype-phenotype validation. Combining sophisticated software with Genedata’s team of scientific consultants, Genedata Selector for Precise Genome Editing provides a full service solution for CRISPR data management and analysis.
Genome editing techniques like CRISPR are revolutionizing molecular biology and equipping scientists with the ability to precisely modify the DNA of essentially any organism. While advances in next-generation sequencing technology have made genome editing faster and easier, researchers still face challenges in efficiently managing and analyzing the experimental data. For example, currently available software tools address only individual steps of the entire experimental process and make the data analysis process very manual and prone to errors. Furthermore, the lack of integrated data management to track results along the experimental process make the performance of precise genome editing experiments in a GxP environment impossible. And finally, lack of data security can cause high risks for IP protection. These are just a few of the many challenges that Genedata Selector for Precise Genome Editing addresses.
Genedata Selector for Precise Genome Editing provides a fully integrated software system for the efficient analysis and management of all CRISPR related experimental data within an organization. Some key features include:
- Genome-wide gRNA prediction with further off-target validation in other organisms (e.g. cloning hosts) to maximize the likelihood for a successful genome editing experiment
- Secure genome data storage of public and proprietary genomes to allow for gRNA design of proprietary genomes while maintaining full IP protection
- Sophisticated data management, including the ability to share data in a flexible yet secure platform across an organization, enables compliance in a GxP environment
Optimized Target Specification
Genedata Selector stores and maintains up-to-date, fully annotated public and proprietary genomes of any organism of interest. The software also includes sophisticated algorithms for comparative genomics, copy-number analysis, statistical expression data analysis, and signaling & metabolic pathway analysis. All of this combined with a built-in patent search provides the most robust platform for CRISPR target selection.
Efficient GuideRNA Selection
Genedata Selector supports the use of all different CRISPR protocols providing researchers with full flexibility in the design of gRNAs. All available gRNAs are automatically tested for uniqueness and off-target binding resulting in the highest quality gRNAs available for selection. Designed gRNAs can be visualized within their genomic context including mutation and transcriptional profiles, sequencing coverage information, and copy number variations, which can be combined with functional protein motif information. This allows researchers to select optimal gRNAs for their specific experiments. All of this information is maintained within the Selector software and can be easily shared with colleagues.
Validated Genotype - Phenotype Relationships
Once a CRISPR experiment has been performed, Genedata Selector can validate the experimental result through sequence analysis. Whether for analyzing targeted locus or whole-genome sequences, Genedata Selector provides automatic workflows for the processing of raw sequence data and comparing sequencing results with reference genomes to validate gene editing results. The software also stores all phenotypic related cell information like growth profiles, expression data, and metabolomics variables for easy genotype-phenotype relationship analysis.
“With Genedata Selector for Precision Genome Editing, we provide a highly valuable platform for a rapidly emerging field,” said Dr. Othmar Pfannes, CEO of Genedata. “I am really excited of this latest advancement of Genedata Selector as it provides organizations, who invest in CRISPR technology, a sophisticated data management and analysis solution for faster and more effective research and product development results.”
About Genedata
Genedata transforms data into intelligence with innovative software solutions and domain-specific consulting services that automate complex, large-scale experimental processes and enable organizations to maximize the ROI from their R&D. Founded in 1997, Genedata is headquartered in Switzerland and has offices in Germany, the UK, Japan, and the US.
http://www.genedata.com
Follow Us on LinkedIn
Disclaimer
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
All product and service names mentioned are the trademarks of their respective companies.
Erin Thome, Genedata Selector Public Relations, http://www.genedata.com, +41 615118417, [email protected]
Share this article